Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | COMT | P21964 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | BAG3 | O95817 | 1/20 | 0.42 |
| ▸ | DVL1 | O14640 | 1/20 | 0.42 |
| ▸ | ESRRA | P11474 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614943 | 0.91 | PIM1 (0.53) | PIM1SLC2A1ALDH1A1COMTPPARG | |
| SCHEMBL12712433 | 0.89 | SLC2A1 (0.56) | PIM1SLC2A1ALDH1A1PPARGNLRP3 | |
| SCHEMBL1614720 | 0.84 | SLC2A1 (0.65) | PIM1SLC2A1ALDH1A1PPARGNLRP3 | |
| SCHEMBL12712455 | 0.82 | ENPP2 (0.57) | ALDH1A1PPARGMEN1KMT2A | |
| SCHEMBL1613781 | 0.81 | PIM1 (0.53) | PIM1SLC2A1ALDH1A1PPARGNLRP3 | |
| SCHEMBL1614533 | 0.80 | NLRP3 (0.55) | PIM1SLC2A1PPARGNLRP3MEN1 | |
| SCHEMBL12712450 | 0.77 | ENPP2 (0.52) | PIM1ALDH1A1COMTPPARGBAG3 | |
| SCHEMBL12712449 | 0.75 | MEN1 (0.50) | ALDH1A1COMTPPARGS1PR1BAG3 | |
| SCHEMBL1614940 | 0.74 | SLC2A1 (0.52) | PIM1SLC2A1ALDH1A1COMTPPARG | |
| SCHEMBL12712457 | 0.74 | COMT (0.53) | SLC2A1ALDH1A1COMTPPARGBAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383656-B2 | Thiazolidinedione energy restriction-mimetic agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110086895-A1 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086895-A1 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS | PCK2, AK2, SIRT6 | PIM1 2193/4885SLC2A1 76/4885ALDH1A1 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.